Erin Bishop

ORCID: 0000-0002-9914-4754
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Endometrial and Cervical Cancer Treatments
  • Ovarian cancer diagnosis and treatment
  • Cervical Cancer and HPV Research
  • Metabolism, Diabetes, and Cancer
  • Endometriosis Research and Treatment
  • Uterine Myomas and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cancer, Lipids, and Metabolism
  • Dark Matter and Cosmic Phenomena
  • Cancer Immunotherapy and Biomarkers
  • Caveolin-1 and cellular processes
  • PARP inhibition in cancer therapy
  • Global Cancer Incidence and Screening
  • Hormonal Regulation and Hypertension
  • PI3K/AKT/mTOR signaling in cancer
  • Neutrino Physics Research
  • Reconstructive Surgery and Microvascular Techniques
  • Cancer Mechanisms and Therapy
  • FOXO transcription factor regulation
  • Gestational Trophoblastic Disease Studies
  • Cancer, Stress, Anesthesia, and Immune Response
  • Cancer Cells and Metastasis
  • Breast Cancer Treatment Studies
  • Astrophysics and Cosmic Phenomena
  • Statistical Methods in Clinical Trials

Medical College of Wisconsin
2015-2024

Froedtert Hospital
2022-2024

Gynecologic Oncology Group
2024

Children's Hospital of Wisconsin
2019

University of Oklahoma
2011-2017

University of Oklahoma Health Sciences Center
2011-2015

Oklahoma City University
2011-2014

National Cancer Institute
2014

University of Chicago Medical Center
2010

Children's of Alabama
1949

Purpose Women with abnormal cervical cancer screening results are referred to colposcopy and biopsy for diagnosis of precursors (high-grade squamous intraepithelial lesions [HSILs]). Colposcopy a single can miss identification HSILs. No systematic study has quantified the improved detection HSIL by taking multiple lesion-directed biopsies. Methods The Biopsy Study was an observational 690 women after results. Up four directed biopsies were taken from distinct acetowhite ranked colposcopic...

10.1200/jco.2014.55.9948 article EN Journal of Clinical Oncology 2014-11-25

The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver chemotherapy resistance. We hypothesized that adding the JAK1/2 inhibitor ruxolitinib to standard would be tolerable improve progression-free survival (PFS) in patients with ovarian cancer upfront setting.

10.1200/jco.23.02076 article EN Journal of Clinical Oncology 2024-05-22

Abstract The XLZD collaboration is developing a two-phase xenon time projection chamber with an active mass of 60–80 t capable probing the remaining weakly interacting massive particle-nucleon interaction parameter space down to so-called neutrino fog. In this work we show that, based on performance currently operating detectors using same technology and realistic reduction radioactivity in detector materials, such experiment will also be able competitively search for neutrinoless double...

10.1088/1361-6471/adb900 article EN cc-by Journal of Physics G Nuclear and Particle Physics 2025-04-22

Abstract Recurrence of therapy-resistant tumors is a principal problem in solid tumor oncology, particularly ovarian cancer. Despite common complete responses to first line, platinum-based therapies, most women with cancer recur, and eventually, nearly all recurrent disease develop platinum resistance. Likewise, both intrinsic acquired resistance contribute the dismal prognosis pancreatic Our previous work that others has established CLPTM1L (cleft lip palate transmembrane protein...

10.1038/s41698-021-00152-9 article EN cc-by npj Precision Oncology 2021-03-02

Ovarian cancer is the most lethal gynecological malignancy among women worldwide and characterized by aggressiveness, stemness, frequent relapse due to resistance platinum-based therapy. cells metastasize through ascites fluid as 3D spheroids which are more resistant apoptosis chemotherapeutic agents. However, precise mechanism an oncogenic addiction that makes agents not understood. To study signaling occurs during progression in patients, we developed endometrioid subtype ovarian cell line...

10.3390/cancers14040958 article EN Cancers 2022-02-15

5510 Background: Patients with metastatic recurrent endometrial cancer have limited effective therapies. Single agent pembrolizumab is utilized in mismatch repair deficient (MMRd) patients, while the combination of lenvatinib and now more commonly used MMR intact patients who progressed after chemotherapy combinations. This trial investigated a novel three drug regimen. Methods: not amenable to curative intent surgery or radiation one two lines therapy were eligible regardless histology....

10.1200/jco.2022.40.16_suppl.5510 article EN Journal of Clinical Oncology 2022-06-01

This report describes the experimental strategy and technologies for a next-generation xenon observatory sensitive to dark matter neutrino physics. The detector will have an active liquid target mass of 60-80 tonnes is proposed by XENON-LUX-ZEPLIN-DARWIN (XLZD) collaboration. design based on mature time projection chamber technology current-generation experiments, LZ XENONnT. A baseline opportunities further optimization individual components are discussed. experiment envisaged here has...

10.48550/arxiv.2410.17137 preprint EN arXiv (Cornell University) 2024-10-22

5501 Background: The Interleukin-6/JAK/STAT3 axis, via an increase in cancer stem-like cell (CSC) survival, is a reported driver of chemotherapy resistance. We hypothesized that addition the JAK1/2 inhibitor ruxolitinib to standard would be tolerable and, by targeting therapy-resistant cells, improve progression-free survival (PFS) ovarian/fallopian tube/primary peritoneal carcinoma (OV/FT/PPC) patients treated up-front setting. Methods: Patients with OV/FT/PPC dispositioned neoadjuvant were...

10.1200/jco.2022.40.16_suppl.5501 article EN Journal of Clinical Oncology 2022-06-01

Elderly endometrial cancer patients have worse disease-specific survival than their younger counterparts, but the cause for this discrepancy is unknown. The goal of analysis to compare outcomes by age in a fully staged elderly population.This an on Gynecologic Oncology Group Study (GOG) LAP2, which included clinically early stage randomized laparotomy versus laparoscopy surgical staging. Patients were divided into risk groups based criteria defined GOG protocol 99. Differences and adjuvant...

10.1097/igc.0000000000000947 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2017-04-08

Background The SNRK (sucrose-nonfermenting-related kinase) enzyme is critical for cardiac function. However, the underlying cause heart failure observed in

10.1161/jaha.119.012792 article EN cc-by-nc-nd Journal of the American Heart Association 2019-11-13

Since the year 1939, when preparations of protein digests became generally available in America, reports investigations designed to test their value parenteral feeding infants have appeared from time time.' Amigen,' an enzymic digest hydrolysed casein, is one these preparations.amounts are contained 'casydrol' (1 7-2 5 per cent.) cent.glucose solution given at a rate about 6 ml. kg.(or 3 ml.per lb.) each hour.Blood and plasma which sometimes as part daily infusion, somewhat lower calorie (20...

10.1136/adc.24.119.159 article EN Archives of Disease in Childhood 1949-09-01

Epidemiological studies suggest an association between elevated insulin levels and endometrial cancer. We studied the effects of on normal cell proliferation with cytotoxicity assays. Organotypic cultures were used to determine development malignant histological features anchorage independent growth. Western Blots analyze mitogen-activated protein kinases AKT pathways. found that exerts direct cells by increasing promoting carcinogenesis. Our results this occurs through ERK 1/2 glycogen...

10.3109/07357907.2013.877479 article EN Cancer Investigation 2014-02-05

Failure to gan or actual loss of weight is a common condition in young infants which has been subjec disussion for centuries, and m the past there was tendency regard wasting as clinical entity.This conception entirely wrong (Parsons, 1924); it but symptom some underlying i this respect comparable wnth odter symptoms such vonming, con- vulions, diarrhoea, none regarded diseae sui generis.The causes severe may be classified under two main headings, (a) insufficient food, (b) presence...

10.1136/adc.24.120.250 article EN Archives of Disease in Childhood 1949-12-01

Objective Incompletely resected epithelial ovarian cancer represents a poor prognostic subset of patients. Novel treatment strategies are needed to improve outcomes for this population. We evaluated strategy combining platinum-based chemotherapy with pembrolizumab followed by maintenance therapy in the first-line after incomplete resection Methods This was single-arm, non-randomized pilot study carboplatin, taxane, and immune checkpoint inhibitor, pembrolizumab, 12 months patients...

10.3389/fonc.2024.1291090 article EN cc-by Frontiers in Oncology 2024-02-12

<h3>Introduction/Background</h3> Effective and well-tolerated treatments for PROC remain an unmet medical need; standard of care single agent chemotherapy has limited efficacy, with response rates at ~12%. Upifitamab rilsodotin (UpRi) is a Dolaflexin, high Drug-to-Antibody Ratio ADC targeting NaPi2b, sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian cancer, expression normal tissues. UPLIFT was single-arm Ph2 trial evaluating the efficacy safety...

10.1136/ijgc-2024-esgo.1118 article EN 2024-03-01

TPS5641 Background: Uterine serous carcinoma and uterine carcinosarcoma are rare, high-risk cancer subtypes that overexpress HER2 in up to 40% 10% of cases, respectively. Phase II data demonstrated a benefit adding trastuzumab positive advanced recurrent carcinoma. Dual anti-HER2 therapy has the potential for further improvement survival. Methods: This is non-blinded, three-arm randomized phase II/III study. The primary objective evaluate efficacy hyaluronidase-oysk (HERCEPTIN HYLECTA) or...

10.1200/jco.2024.42.16_suppl.tps5641 article EN Journal of Clinical Oncology 2024-06-01

We report results of a search for nuclear recoils induced by weakly interacting massive particle (WIMP) dark matter using the LUX-ZEPLIN (LZ) two-phase xenon time projection chamber. This analysis uses total exposure $4.2\pm0.1$ tonne-years from 280 live days LZ operation, which $3.3\pm0.1$ and 220 are new. A technique to actively tag background electronic $^{214}$Pb $\beta$ decays is featured first time. Enhanced electron-ion recombination observed in two-neutrino double electron capture...

10.48550/arxiv.2410.17036 preprint EN arXiv (Cornell University) 2024-10-22

Abstract The broad physics reach of the LUX-ZEPLIN (LZ) experiment covers rare phenomena beyond direct detection dark matter. We report precise measurements extremely decay 124 Xe through process two-neutrino double electron capture, utilizing a 1.39 kg × yr isotopic exposure from first LZ science run. A half-life <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" overflow="scroll"> <mml:msubsup> <mml:mi>T</mml:mi> <mml:mrow> <mml:mn>1</mml:mn> <mml:mo>/</mml:mo> <mml:mn>2</mml:mn>...

10.1088/1361-6471/ad9039 article EN cc-by Journal of Physics G Nuclear and Particle Physics 2024-12-06

Therapeutic options for recurrent adult granulosa cell tumors (AGCT) are limited. After examining the hormonal pathways involved in

10.1016/j.gore.2022.101118 article EN cc-by-nc-nd Gynecologic Oncology Reports 2022-12-01
Coming Soon ...